Article

$37 million raised for start up of Optherion Inc.

New Haven, CT-Optherion, Inc has raised $37 million in start-up financing. The company is developing products to diagnose and treat dry and wet age-related macular degeneration.

New Haven, CT-Optherion, Inc has raised $37 million in start-up financing. The company is developing products to diagnose and treat dry and wet age-related macular degeneration.

Founded following discoveries published in 2005 linking the role of complement factor H (CFH) and complement factor B (CFB), the company's intellectual property estate is based on discoveries at the University of Iowa by Dr. Gregory Hageman and at Yale University and Rockefeller University by Dr. Josephine Hoh as well as other universities.

Capital financing sources include Quaker Bioventures, Philadelphia; Domain Associates, Princeton, NJ, and San Diego; Johnson and Johnson Development Corp., New Brunswick NJ.

Optherion's chief scientific officer is Dr. Hageman, the scientific founder of Optherion and a co-discoverer of the relationship of the relationship of the genetics of CFH and CFB do AMD. He is the Iowa Entrepreneurial Endowed professor in the Department of Ophthalmology and Visual Sciences at the University of Iowa.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
© 2025 MJH Life Sciences

All rights reserved.